

* The files listed above are temporarily unavailable.

FILE 'USPAT' ENTERED AT 14:27:15 ON 13 SEP 1997

```
* * * * *
*           W E L C O M E   T O   T H E           *
*           U . S .   P A T E N T   T E X T   F I L E           *
* * * * *
```

=> s adenovir? and vector?

2086 ADENOVIR?

59812 VECTOR?

L1 1471 ADENOVIR? AND VECTOR?

=> s l1 and protein IX

55008 PROTEIN

61465 IX

146 PROTEIN IX

(PROTEIN(W) IX)

L2 23 L1 AND PROTEIN IX

=> d 12,1-23,cit

1. 5,658,882, Aug. 19, 1997, Methods of inducing formation of tendon and/or ligament tissue comprising administering BMP-12, BMP-13, and/or MP-52; Anthony J. Celeste, et al., 514/12; 435/69.1, 252.3, 320.1, 375; 514/2, 8; 530/350, 399; 536/23.4, 23.5 :IMAGE AVAILABLE:

2. 5,652,223, Jul. 29, 1997, DNA encoding CAI resistance proteins and uses thereof; Elise C. Kohn, et al., 514/44; 435/91.1, 91.5, 172.3, 320.1; 536/23.1, 23.2, 23.5; 935/9, 14 :IMAGE AVAILABLE:

3. 5,652,123, Jul. 29, 1997, Protein having interleukin 13 activity, recombinant DNA coding for this protein, transformed cells and microorganisms; Daniel Caput, et al., 435/69.52; 424/85.2; 435/252.33, 254.2, 320.1, 325, 358, 360, 365.1; 530/351; 536/23.5 :IMAGE AVAILABLE:

4. 5,646,115, Jul. 8, 1997, Ectoparasite saliva proteins and apparatus to collect such proteins; Glenn R. Frank, et al., 514/12; 424/185.1, 275.1; 530/300, 324, 858 :IMAGE AVAILABLE:

5. 5,641,875, Jun. 24, 1997, DNA encoding chimeric IgG Fc receptor; Alan D. Schreiber, et al., 536/23.4; 435/69.7, 252.3, 320.1; 530/350 :IMAGE AVAILABLE:

6. 5,641,863, Jun. 24, 1997, Chimeric IgG Fc receptors; Alan D. Schreiber, et al., 530/350; 435/69.7; 536/23.7 :IMAGE AVAILABLE:

7. 5,606,029, Feb. 25, 1997, Gene for a growth factor and its cDNA and protein; Sandra J. Degen, 530/399; 536/23.5 :IMAGE AVAILABLE:

8. 5,605,690, Feb. 25, 1997, Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor; Cindy A. Jacobs, et al., 424/134.1; 435/69.7; 514/12, 825; 530/350, 387.3, 866, 868 :IMAGE AVAILABLE:

9. 5,604,201, Feb. 18, 1997, Methods and reagents for inhibiting furin endoprotease; Gary Thomas, et al., 514/12; 435/252.3, 254.2, 320.1; 530/350; 536/23.5 :IMAGE AVAILABLE:

10. 5,595,904, Jan. 1997, Family of map2 protein kinases; Teri G. Boulton, et al., 435/325, 243, 252.8, 254.2, 320.1, 348, 353; 536/23.5 :IMAGE AVAILABLE:
11. 5,594,101, Jan. 14, 1997, Anti-obesity proteins; Gerald W. Becker, et al., 530/317, 324, 350 :IMAGE AVAILABLE:
12. 5,552,529, Sep. 3, 1996, Autoantigen, pinch; Ann Rearden, 530/380; 424/185.1; 530/327, 806, 829 :IMAGE AVAILABLE:
13. 5,534,256, Jul. 9, 1996, Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins; Andrew A. Potter, et al., 424/184.1, 193.1, 203.1, 236.1, 255.1, 256.1, 278.1, 282.1 :IMAGE AVAILABLE:
14. 5,532,348, Jul. 2, 1996, E6 associated protein and methods of use thereof; Jon M. Huibregtse, et al., 536/23.5; 435/235.1 :IMAGE AVAILABLE:
15. 5,492,825, Feb. 20, 1996, Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding **vectors**, and transformed cells; Lily Y. Jan, et al., 435/352, 69.1, 252.31, 254.11, 320.1; 536/23.5 :IMAGE AVAILABLE:
16. 5,470,734, Nov. 28, 1995, Recombinant herpesvirus of turkeys and live **vector** vaccines derived thereof; Paulus J. A. Sondermeijer, et al., 424/229.1, 211.1, 214.1, 816; 435/235.1; 536/23.72 :IMAGE AVAILABLE:
17. 5,468,845, Nov. 21, 1995, Antibodies to osteogenic proteins; Hermann Oppermann, et al., 530/387.9, 350 :IMAGE AVAILABLE:
18. 5,462,925, Oct. 31, 1995, Transforming growth factor .beta.2,3; Yasushi Ogawa, et al., 514/12; 530/324, 350, 399; 930/10, 120 :IMAGE AVAILABLE:
19. 5,354,664, Oct. 11, 1994, DNA encoding a human thrombomodulin having a modified glycosaminoglycan (GAG) binding site; Takeshi Doi, et al., 435/69.1, 320.1, 348, 357, 358, 367, 372; 530/381; 536/23.1, 23.5 :IMAGE AVAILABLE:
20. 5,354,557, Oct. 11, 1994, Osteogenic devices; Hermann Oppermann, et al., 424/423, 422, 424, 426 :IMAGE AVAILABLE:
21. 5,273,962, Dec. 28, 1993, Human urinary thrombomodulin with a modified glycosaminoglycan (GAG) binding site; Takeshi Doi, et al., 514/8; 435/69.1, 69.3; 514/2; 530/380, 381 :IMAGE AVAILABLE:
22. 5,266,683, Nov. 30, 1993, Osteogenic proteins; Hermann Oppermann, et al., 530/326, 327, 328, 350, 395, 840 :IMAGE AVAILABLE:
23. 4,593,002, Jun. 3, 1986, Viruses with recombinant surface proteins; Renato Dulbecco, 435/172.3; 424/199.1, 217.1, 224.1, 233.1; 435/69.1, 69.3, 91.41, 235.1, 239, 317.1; 536/23.1; 935/12, 31, 32, 65 :IMAGE AVAILABLE:

=> d kwic,15

US PAT NO: 5,492,825 :IMAGE AVAILABLE: L2: 15 of 23
 TITLE: Mammalian inward rectifier potassium channel cDNA, IRK1,
 corresponding **vectors**, and transformed cells

SUMMARY:

BSUM(23)

In . . . the IRK1 (SEQ. ID NO: 2) and GIRK1 (SEQ. ID NO: 4) gene products or functionally bioactive equivalents thereof and **vectors** and transfectants operatively harboring same. In a preferred embodiment, the DNA encodes the IRK1 gene product (SEQ. ID NO: 2) . . .

SUMMARY:

BSUM(24)

In . . . transfected cell harboring either of the inward rectifier K.sup.+ channel genes is a Xenopus oocyte. A further preferred embodiment provides **vectors** comprising the DNA encoding either the IRK1 or GIRK1 (SEQ. ID NO: 4) gene products (SEQ. ID NO: 2) or. . .

SUMMARY:

BSUM(25)

The . . . NO: 2) and GIRK1 (SEQ. ID NO: 4) gene products or functionally bioactive equivalents. It is further directed to expression **vectors** harboring such DNA comprising expression control elements operative in the recombinant host selected for the expression of such DNA and. . . appropriate initiation (i.e., promoter and enhancer elements), termination, replication, and other sequences that functionally assist the integration of the expression **vector** into a recombinant host by transfection, optionally coupled with actual integration into the host's genome.

SUMMARY:

BSUM(26)

In . . . to IRK1 (SEQ. ID NO: 1) or GIRK1 (SEQ. ID NO: 3) gene sequences under low stringency conditions; devising expression **vectors** for them; and producing transfected hosts.

DETDESC:

DETD(14)

By . . . respective DNA sequences are operational, that is, work for their intended purposes. Thus, the DNA is preferably contained within expression **vectors** that are used to transfect recombinantly suitable host cells. The **vectors** and methods disclosed herein are suitable for use in host cells over a wide range of prokaryotic and eukaryotic organisms. "Transfectants" refers to cells and viruses which have been transfected or transformed with **vectors** constructed using recombinant DNA techniques, including expression systems including but not limited to, Xenopus and vaccina.

DETDESC:

DETD(15)

In general, prokaryotes are preferred for cloning of DNA sequences in constructing the **vectors** useful in the invention. For example, E. coli DH10B (Gibco BRL) is particularly useful. Other microbial strains which may be. . .

DETDESC:

DETD(17)

In general, plasmid **vectors** containing replicon and control sequences which are derived from species compatible with the host cell

are used in connection with these hosts. The **vector** ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transfected cells. . . . utilized, and details concerning their nucleotide sequence have been published, enabling a skilled worker to ligate them functionally with plasmid **vectors** :Siebenlist, et al., Cell 20, 269 (1980):.

DETDESC:

DETD(18)

Additionally, phage **vectors** may be utilized in place of plasmid **vectors**. Examples of suitable phage **vectors** are provided in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, New York, 1989.

DETDESC:

DETD(20)

Suitable promoting sequences in yeast **vectors** include the promoters for 3-phosphoglycerate kinase :Hitzeman, et al., J. Biol. Chem. 255, 12073 (1980): or other glycolytic enzymes :Hess, . . . and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression **vector** 3' of the sequences desired to be expressed to provide polyadenylation of the mRNA and termination. Other promoters, which have. . . with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization (Holland, ibid.). Any plasmid **vector** containing yeast compatible promoter, origin of replication and termination sequences is suitable.

DETDESC:

DETD(21)

In . . . COS-7 and MDCK cell lines. One such useful cell line is a CHO line, CHO-K1 ATCC No. CCL 61. Expression **vectors** for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of the gene to. . . .

DETDESC:

DETD(22)

For invertebrate cells, the control functions on the expression **vectors** are often provided by viral material derived from Baculovirus. For mammalian cells, the control functions on the expression **vectors** are also often provided by viral material. For example, commonly used promoters are derived from polyoma, **Adenovirus** 2, Rous sarcoma virus, cytomegalovirus, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus. . . .

DETDESC:

DETD(23)

An origin of replication may be provided either by construction of the **vector** to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV, etc.) source, or may be provided by the host cell chromosomal replication mechanism. If the **vector** is integrated into the host cell chromosomes, the latter is often sufficient.

DETDESC:

DETD(26)

Construction of suitable **vectors** containing the desired coding and control sequences employ standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and. . .

DETDESC:

DETD(30)

For . . . tailored to provide correct matching are treated with about 10 units T4 DNA ligase per 0.5 .mu.g DNA. (When cleaved **vectors** are used as components, it may be useful to prevent religation of the cleaved **vector** by pretreatment with bacterial alkaline or calf intestinal phosphatase.)

DETDESC:

DETD(37)

The . . . example, its reactive determinant(s). They may synthesize the underlying DNA sequence for deployment within similar or other suitable, operative expression **vectors** and culture systems. They may use the sequences herein to create probes, preferably from regions at both the N-terminus and. . .

SYSTEM LIMITS EXCEEDED - DISPLAY ENDED

=> s l1 and IX

61465 IX
L3 573 L1 AND IX

=> s l1 and proteinIX

0 PROTEINIX
L4 0 L1 AND PROTEINIX

attachment to
Page #17

=> s adenovirus? and E1A
 1621 ADENOVIRUS?
 202 E1A
 L1 76 ADENOVIRUS? AND E1A
 => s l1 and recombinant?
 10371 RECOMBINANT?
 L2 65 L1 AND RECOMBINANT?
 => s l2 and protein IX
 50522 PROTEIN
 58711 IX
 106 PROTEIN IX
 (PROTEIN(W) IX)
 L3 0 L2 AND PROTEIN IX
 => s l3 and vector?
 55303 VECTOR?
 L4 0 L3 AND VECTOR?
 => s l2 and vector?
 55303 VECTOR?
 L5 64 L2 AND VECTOR?
 => s l5 and tumor suppressor?
 13721 TUMOR
 5855 SUPPRESSOR?
 123 TUMOR SUPPRESSOR?
 (TUMOR(W) SUPPRESSOR?)
 L6 10 L5 AND TUMOR SUPPRESSOR?
 => d 16,1-10,cit,ab

1. 5,576,206, Nov. 19, 1996, Human papilloma virus genes and their use in gene therapy; Richard Schlegel, 435/240.2, 320.1 [IMAGE AVAILABLE]

US PAT NO: 5,576,206 [IMAGE AVAILABLE] L6: 1 of 10

ABSTRACT:

A process of immortalizing cells with isolated HPV-16, 18, 31, 33 or 35 E6 and E7 genes or the E7 gene alone to produce non-tumorigenic immortalized cell lines which retain the differentiated phenotypic characteristics of the parent cells.

2. 5,569,824, Oct. 29, 1996, Transgenic mice containing a disrupted p53 gene; Lawrence A. Donehower, et al., 800/2; 424/9.1 [IMAGE AVAILABLE]

US PAT NO: 5,569,824 [IMAGE AVAILABLE] L6: 2 of 10

ABSTRACT:

A desired non-human animal or an animal cell or human cell which contains a predefined, specific and desired alteration in at least one of its two p53 chromosomal alleles, such that at least one of these alleles contains a mutation which alters the expression of the allele, and the other of the alleles expresses either a normal p53 gene product, or comprises an identical or different p53 mutation.

3. 5,550,316, Aug. 27, 1996, Transgenic animal model system for human cutaneous melanoma; Beatrice Mintz, 800/2; 424/9.2; 435/172.3; 536/23.1, 23.72, 24.1; 800/DIG.1 [IMAGE AVAILABLE]

US PAT NO: 5,550,316 [IMAGE AVAILABLE] L6: 3 of 10

ABSTRACT:

The present invention relates to transgenic animal model systems for human cutaneous melanoma. It is based, at least in part, on the discovery that, in susceptible transgenic mice, accelerated formation of melanoma tumors occurred near the wound borders of skin grafts carrying the Tyr-SV40E transgene, indicating that factors present during wound healing facilitate the formation of cutaneous melanoma in susceptible tissue.

4. 5,532,340, Jul. 2, 1996, **Tumor** **suppressor** protein PRB2, related gene products, and DNA encoding therefor; Antonio Giordano, 530/350; 536/23.5; 930/220; 935/9, 29 [IMAGE AVAILABLE]

US PAT NO: 5,532,340 [IMAGE AVAILABLE]

L6: 4 of 10

ABSTRACT:

The invention provides a **tumor** **suppressor** protein of the retinoblastoma family (pRb2) which binds to the **E1A** transforming domain and to DNA encoding for the pRb2 protein.

5. 5,532,124, Jul. 2, 1996, Genetically engineered bacteria to identify and produce medically important agents; Timothy M. Block, et al., 435/5, 6, 23, 34, 68.1, 69.1, 69.2, 184, 244, 252.3, 974 [IMAGE AVAILABLE]

US PAT NO: 5,532,124 [IMAGE AVAILABLE]

L6: 5 of 10

ABSTRACT:

Microorganisms modified such that their growth in selective media is dependent upon the inhibition of a medically important target function are provided and utilized in methods for the screening of potential medically important compounds.

6. 5,473,056, Dec. 5, 1995, E2F-2, a novel mammalian transcription factor; Mona Ivey-Hoyle, et al., 530/358; 536/23.5 [IMAGE AVAILABLE]

US PAT NO: 5,473,056 [IMAGE AVAILABLE]

L6: 6 of 10

ABSTRACT:

The present invention is directed to a novel protein with E2F-like properties and the cDNA that encodes for that protein. The purified protein exhibits biological activity which is deemed important to medical science in the study of cell cycle regulation in general and the specific study of the Rb tumor suppressor protein and certain viral oncogenes. The protein may be employed in a complex with pRb or other cellular proteins to study inhibitors of biochemical transformations of those proteins, such as for example the phosphorylation of the pRb portion of the complex, therefore aiding in the study of potential pharmaceutical agents useful against certain oncoproteins encoded by DNA tumor viruses.

7. 5,457,049, Oct. 10, 1995, **Tumor** **suppressor** protein pRb2, related gene products, and DNA encoding therefor; Antonio Giordano, 435/252.33, 91.1, 172.3, 252.3, 320.1, 849; 530/350; 536/23.1, 23.5; 935/9, 29, 73 [IMAGE AVAILABLE]

US PAT NO: 5,457,049 [IMAGE AVAILABLE]

L6: 7 of 10

ABSTRACT:

The invention provides a **tumor** **suppressor** protein of the retinoblastoma family (pRb2) which binds to the **E1A** transforming

domain and to DNA encoding for the pRb2 protein.

8. 5,376,542, Dec. 27, 1994, Method for producing immortalized cell lines using human papilloma virus genes; Richard Schlegel, 435/172.2, 172.3, 240.1, 240.2; 935/62, 71, 93 [IMAGE AVAILABLE]

US PAT NO: 5,376,542 [IMAGE AVAILABLE]

L6: 8 of 10

ABSTRACT:

A process of immortalizing cells with isolated HPV-16, 18, 31, 33 or 35 E6 and E7 genes or the E7 gene alone to produce non-tumorigenic immortalized cell lines which retain the differentiated phenotypic characteristics of the parent cells.

9. 5,302,519, Apr. 12, 1994, Method of producing a Mad polypeptide; Elizabeth M. Blackwood, et al., 435/69.1, 6, 69.3, 70.21, 240.2; 530/350, 351; 536/23.1, 23.5 [IMAGE AVAILABLE]

US PAT NO: 5,302,519 [IMAGE AVAILABLE]

L6: 9 of 10

ABSTRACT:

Nucleic acid molecules capable of hybridizing under stringent conditions to the nucleotide sequence residing between positions 1 and 453 of the max cDNAs shown in FIG. 2, or to the nucleotide sequence residing between positions 148 and 810 of the mad cDNAs shown in FIG. 14. The Max polypeptide when associated with the Myc or Mad polypeptide is capable of binding to nucleotide sequences containing CACGTG.

10. 5,262,321, Nov. 16, 1993, DNA encoding p107 **tumor**
suppressor; David M. Livingston, et al., 435/240.2, 252.3, 252.33;
536/23.5 [IMAGE AVAILABLE]

US PAT NO: 5,262,321 [IMAGE AVAILABLE]

L6: 10 of 10

ABSTRACT:

A cDNA encodes p107; a cell contains **recombinant** p107-encoding DNA; and substantially all of the cells of a nonhuman mammal contain **recombinant** p107-encoding DNA. Also, a method for diagnosing a condition of tumorigenicity in a subject, includes the steps of obtaining a tissue sample from the subject and detecting the presence of non wild-type p107-encoding gene in the sample, or detecting the absence of wild-type p107-encoding gene in the sample; or extracting DNA from the sample and detecting the presence of non wild-type p107-encoding gene or the absence of wild-type p107-encoding gene in the DNA. Also, a nucleic acid probe is complementary to a portion of a human mutant p107 gene.

=

35555 ADENOVIR?
 814961 TUMOR
 439516 SUPPRESS?
 17439 TUMOR(W) SUPPRESS?
 59311 ANTITUMOR
 21231 P53
 19242 RB
 12 MITOSIN
 43821 SUICIDE
 158478 TOXIN

S6 1491 ADENOVIR? AND (TUMOR(W) SUPPRESS? OR ANTITUMOR OR P53 OR
 RB OR MITOSIN OR SUICIDE OR TOXIN)

?s s6 and (vector or vehicle or gene(w)therapy)

Processing

1491 S6
 117809 VECTOR
 257360 VEHICLE
 1009981 GENE
 3337615 THERAPY
 14887 GENE(W) THERAPY

S7 214 S6 AND (VECTOR OR VEHICLE OR GENE(W) THERAPY)

?rd

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

...examined 50 records (50)
 ...examined 50 records (100)
 ...examined 50 records (150)
 ...examined 50 records (200)
 ...completed examining records
 S8 126 RD (unique items)

?s s8 and py<1994

Processing

db-get mb fail1 213696 8796096 1

Processing

Processing

Processing

126 S8
 25564966 PY<1994

S9 21 S8 AND PY<1994

?t s9/3/1-21

9/3/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

08695313 94010313

Specific interaction between *adenoviral* 55-kDa E1B protein and in vivo
 produced *p53* fusion proteins.

Chumakov A; Koeffler HP

Department of Medicine, Cedars-Sinai Medical Center, UCLA School of
 Medicine 90048.

Gene (NETHERLANDS) Sep 15 *1993*, 131 (2) p231-6, ISSN 0378-1119

. Journal Code: FOP

Contract/Grant No.: DK42792, DK, NIDDK; DK41936, DK, NIDDK; CA42710, CA, NCI; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

08208721 92346721

Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties.

Kaelin WG Jr; Krek W; Sellers WR; DeCaprio JA; Ajchenbaum F; Fuchs CS; Chittenden T; Li Y; Farnham PJ; Blonar MA; et al

Dana Farber Cancer Institute, Boston, Massachusetts.

Cell (UNITED STATES) Jul 24 *1992*, 70 (2) p351-64, ISSN 0092-8674

Journal Code: CQ4

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

07969169 92107169

Oncogenes result in genomic alterations that activate a transcriptionally silent, dominantly selectable reporter gene (neo).

Drews RE; Chan VT; Schnipper LE

Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215.

Mol Cell Biol (UNITED STATES) Jan *1992*, 12 (1) p198-206, ISSN

0270-7306 Journal Code: NGY

Contract/Grant No.: HL07516, HL, NHLBI; AG-00294, AG, NIA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

07772724 91291724

Reintroduction of a normal retinoblastoma gene into retinoblastoma and osteosarcoma cells inhibits the replication associated function of SV40 large T antigen.

Uzvolgyi E; Classon M; Henriksson M; Huang HJ; Szekely L; Lee WH; Klein G; Sumegi J

Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.

Cell Growth Differ (UNITED STATES) Jun *1991*, 2 (6) p297-303, ISSN

1044-9523 Journal Code: AYH

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/5 (Item 5 from file: 155)

. DIALOG(R) File 155: MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

06090388 87064388

Recombinant retroviruses encoding simian virus 40 large T antigen and polyomavirus large and middle T antigens.

Jat PS; Cepko CL; Mulligan RC; Sharp PA

Mol Cell Biol (UNITED STATES) Apr *1986*, 6 (4) p1204-17, ISSN 0270-7306 Journal Code: NGY

Contract/Grant No.: R01-GM32467; P01-CA26717; P01-CA14051; +

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/6 (Item 1 from file: 55)

DIALOG(R) File 55: BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

10228548 BIOSIS Number: 45028548

ADENOVIRUS VECTORS FOR *GENE* *THERAPY* OF CANCER

WILLS K N; MENZEL P

CANJI INC., 3038 SCIENCE PARK RD., SAN DIEGO, CA 92121, USA.

KEYSTONE SYMPOSIUM ON GENETICALLY TARGETED RESEARCH AND THERAPEUTICS: ANTISENSE AND GENE THERAPY, KEYSTONE, COLORADO, USA, APRIL 12-18, 1993. J CELL BIOCHEM SUPPL 0 (17 PART E) 1993. 204. CODEN: JCBSD

Language: ENGLISH

Document Type: CONFERENCE PAPER

ILL

9/3/7 (Item 2 from file: 55)

DIALOG(R) File 55: BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

10110790 BIOSIS Number: 95110790

ENHANCED C-ERBB-2-NEU EXPRESSION IN HUMAN OVARIAN CANCER CELLS CORRELATES WITH MORE SEVERE MALIGNANCY THAT CAN BE SUPPRESSED BY E1A

YU D; WOLF J K; SCANLON M; PRICE J E; HUNG M-C

DEP. TUMOR BIOL., BOX 79, UNIV. TEXAS M.D. ANDERSON CANCER CENTER, 1515 HOLCOMBE BOULEVARD, HOUSTON, TX 77030, USA.

CANCER RES 53 (4). 1993. 891-898. CODEN: CNREA

Full Journal Title: Cancer Research

Language: ENGLISH

9/3/8 (Item 3 from file: 55)

DIALOG(R) File 55: BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

8117310 BIOSIS Number: 91038310

SELECTIVE INDUCTION OF TOXICITY TO HUMAN CELLS EXPRESSING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TAT BY A CONDITIONALLY CYTOTOXIC *ADENOVIRUS* *VECTOR*

VENKATESH L K; ARENS M Q; SUBRAMANIAN T; CHINNADURAI G

INST. FOR MOL. VIROL., SAINT LOUIS UNIV. MED. CENT., 3681 PARK AVE., SAINT LOUIS, MO. 63110.

PROC NATL ACAD SCI U S A 87 (22). 1990. 8746-8750. CODEN: PNASA

Full Journal Title: Proceedings of the National Academy of Sciences of the United States of America

microfilm

Q11. N26

Language: ENGLISH

9/3/9 (Item 4 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1996 BIOSIS. All rts. reserv.

5358575 BIOSIS Number: 82003378
RECOMBINANT RETROVIRUSES ENCODING SV-40 LARGE T ANTIGEN AND POLYOMAVIRUS
LARGE AND MIDDLE T ANTIGENS
JAT P S; CEPKO C L; MULLIGAN R C; SHARP P A
CENT. CANCER RES., DEP. BIOL., MASS. INST. TECHNOL., CAMBRIDGE, MASS.
02139.
MOL CELL BIOL 6 (4). 1986. 1204-1217. CODEN: MCEBD
Full Journal Title: Molecular and Cellular Biology
Language: ENGLISH

9/3/10 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abstracts Online
(c) 1996 UMI. All rts. reserv.

01256783 ORDER NO: AAD92-36697
PURIFICATION AND CHARACTERIZATION OF THE *ADENOVIRUS* 2 E1A 243R PROTEIN IN
ESCHERICHIA COLI (E1A PROTEIN)
Author: WANG, DUEN-MEI
Degree: PH.D.
Year: *1992*
Corporate Source/Institution: COL. OF MEDICINE AND DENTISTRY OF N.J.
GRAD. SCH. OF BIOMED. SCIENCE (0301)
Source: VOLUME 53/08-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 3944. 125 PAGES

9/3/11 (Item 2 from file: 35)
DIALOG(R)File 35:Dissertation Abstracts Online
(c) 1996 UMI. All rts. reserv.

0956413 ORDER NO: AAD87-12520
MUTATIONAL ANALYSES OF THE CELLULAR TUMOR ANTIGEN, *P53*; AND
IDENTIFICATION OF THE CELLULAR P68-*P53* PROTEIN COMPLEX
Author: TAN, TSE-HUA
Degree: PH.D.
Year: *1987*
Corporate Source/Institution: PRINCETON UNIVERSITY (0181)
Source: VOLUME 48/03-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 662. 215 PAGES

9/3/12 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

9039509 EMBASE No: 93343499
Inhibition of cell proliferation by an *adenovirus* *vector* expressing
the human wild type *p53* protein
Bacchetti S.; Graham F.L.
Department of Pathology, McMaster University, Hamilton, Ont. L8S 3Z5

Canada

INT. J. ONCOL. (Greece) , *1993*, 3/5 (781-788) CODEN: IJONE ISSN:
1019-6439

LANGUAGES: English SUMMARY LANGUAGES: English

9/3/13 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

9029569 EMBASE No: 93333297

Generation and identification of recombinant *adenovirus* by liposome-mediated transfection and PCR analysis

Zhang W.-W.; Fang X.; Branch C.D.; Mazur W.; French B.A.; Roth J.A.
Thoracic/Cardiovascular Surg. Dept., Texas Univ. M.D. Anderson Can. Ctr.,
Box 109, 1515 Holcombe Boulevard, Houston, TX 77030 USA

BIOTECHNIQUES (USA) , *1993*, 15/5 (868+870-872) CODEN: BTNQD ISSN:
0736-6205

LANGUAGES: English SUMMARY LANGUAGES: English

9/3/14 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

8937874 EMBASE No: 93241699

Potential application of *gene* *therapy* to lung cancer

Tang D.-C.; Carbone D.P.

Department of Internal Medicine, Simmons Cancer Center, University of
Texas SW Medical Ctr., 5323 Harry Hines Blvd, Dallas, TX 75235-8593 USA

SEMIN. ONCOL. (USA) , *1993*, 20/4 (368-373) CODEN: SOLGA ISSN:
0093-7754

LANGUAGES: English

RC 261.4313

9/3/15 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

8882046 EMBASE No: 93186077

Gene *therapy*: A bold direction for HIV-1 treatment

Sarver N.; Rossi J.

NIAD, Division of AIDS, 6003 Executive Blvd, Bethesda, MD 20892 USA

AIDS RES. HUM. RETROVIRUSES (USA) , *1993*, 9/5 (483-487) CODEN: ARHRE
ISSN: 0889-2229

LANGUAGES: English

9/3/16 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

8724610 EMBASE No: 93028710

Opportunities 'opening up' for *gene* *therapy*

Vanchieri C.

J. NATL. CANCER INST. (USA) , *1993*, 85/2 (90-91) CODEN: JNCIA ISSN:
0027-8874

LANGUAGES: English

TL

9/3/17 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

8390171 EMBASE No: 92066113
Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations
O'Hagan D.T.
Department of Pharmaceutical Sciences, University of Nottingham,
University Park, Nottingham NG7 2RD United Kingdom
CLIN. PHARMACOKIN. (New Zealand) , *1992*, 22/1 (1-10) CODEN: CPKND
ISSN: 0312-5963
LANGUAGES: English

9/3/18 (Item 1 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1996 Derwent Info Ltd. All rts. reserv.

look at hits

009458956 WPI Acc No: 93-152482/18
XRAM Acc No: C93-068121
Immunological carrier system with enhanced immunogenicity - comprises
chimeric protein comprising *leucotoxin* peptide or homologous protein
fused to antigen esp. somatostatin or gonadotropin releasing hormone
Patent Assignee: (UYSA-) UNIV SASKATCHEWAN
Author (Inventor): HUGHES H P A; POTTER A A; REDMOND M J
Patent Family:

CC Number	Kind	Date	Week	
WO 9308290	A1	930429	9318	(Basic)
AU 9226991	A	930521	9336	
US 5422110	A	950606	9528	

Priority Data (CC No Date): US 960932 (921014); US 779171 (911016)
Applications (CC,No,Date): WO 92CA449 (921015); AU 9226991 (921015)

9/3/19 (Item 2 from file: 351)
DIALOG(R)File 351:DERWENT WPI
(c)1996 Derwent Info Ltd. All rts. reserv.

008474248 WPI Acc No: 90-361248/48
Related WPI Accession(s): 91-353507
XRAM Acc No: C90-156956
XRPX Acc No: N90-275659
Endothelial cell adhesion mols. - milas and DNA encoding them and
inhibition-detection of binding of leukocytes to endothelial cells;
LEUCOCYTE ADHESIVE
Patent Assignee: (BIOJ) BIOGEN INC
Author (Inventor): BENJAMIN C D; GOELZ S E; HESSION C A; LOBB R R; OSBORN L
; ROSA M D; BORN L; HESSION C
Patent Family:

CC Number	Kind	Date	Week	
WO 9013300	A	901115	9048	(Basic)
AU 9060492	A	901129	9109	
NO 9005553	A	910227	9123	
EP 458911	A	911204	9149	

JP 4502859	W	920528	9228
US 5217870	A	930608	9324
AU 638041	B	930617	9331
US 5272263	A	931221	9351
US 5367056	A	941122	9501
EP 458911	A4	920909	9523

Priority Data (CC No Date): US 452675 (891218); US 345151 (890428); US 359516 (890601); AU 9060492 (900427); US 35674 (930323)

Applications (CC,No,Date): EP 90911366 (); EP 90911366 (900427); JP 90510560 (900427); WO 90US2357 (900427); US 345151 (890428); US 345151 (890428); US 359516 (890601); US 452675 (891218)

9/3/20 (Item 1 from file: 358)
 DIALOG(R)File 358:Current Biotech Abs
 (c)1996 Royal Soc Chem & the DECHEMA. All rts. reserv.

059805 CBA Acc. No.: 12-03-001492 DOC. TYPE: Journal
 New *gene* *therapy* company targets gene mutation associated with cancer.
 CORPORATE SOURCE: Canji Inc., San Diego, CA 92121, USA
 JOURNAL: Biotechnology News Volume: 13 Issue: 21 Page(s): 4-5
 CODEN: BINWEY ISSN: 02733226
 PUBLICATION DATE: 10 Sep 1993 (930910) LANGUAGE: English QH442.M3

easy to antidote

9/3/21 (Item 2 from file: 358)
 DIALOG(R)File 358:Current Biotech Abs
 (c)1996 Royal Soc Chem & the DECHEMA. All rts. reserv.

018521 CBA Acc. No.: 05-02-000571 DOC. TYPE: Journal
 Regulated expression of a diphtheria *toxin* A-chain gene transfected into human cells: possible strategy for inducing cancer cell *suicide*.
 AUTHOR: Maxwell, I. H.; Maxwell, F.; Glode, L. M.
 CORPORATE SOURCE: Univ. Colorado Health Sci. Center, Div. Med. Oncol., Denver, CO 80262, USA
 JOURNAL: Cancer Res. Volume: 46 Issue: 9 Page(s): 4660-4664
 CODEN: CNREA8 ISSN: 0008-5472
 PUBLICATION DATE: Sep 1986 (860900) LANGUAGE: English

?

RC261.A1C2

also check microfilm

870466 EARLY
846547 REGION
3983 EARLY(W)REGION
177158 DELET?
S1 797 EARLY(W)REGION AND DELET?
?s s1 and adenovir?

797 S1
35555 ADENOVIR?
S2 405 S1 AND ADENOVIR?
?s s2 and py<1994

Processing
Processing
Processing
Processing

405 S2
25564966 PY<1994
S3 362 S2 AND PY<1994
?s s3 and (vector or vehicle or (gene(w)therapy))

Processing

362 S3
117809 VECTOR
257360 VEHICLE
1009981 GENE
3337615 THERAPY
14887 GENE(W)THERAPY
S4 35 S3 AND (VECTOR OR VEHICLE OR (GENE(W)THERAPY))
?rd

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records

S5 17 RD (unique items)
?t s5/3/1-35

5/3/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

08687368 94002368

Development and analysis of recombinant *adenoviruses* for *gene*
therapy of cystic fibrosis.

Rich DP; Couture LA; Cardozá LM; Guiggio VM; Armentano D; Espino PC;
Hehir K; Welsh MJ; Smith AE; Gregory RJ

Genzyme Corporation, Framingham, MA 01701.

Hum Gene Ther (UNITED STATES) Aug *1993*, 4 (4) p461-76, ISSN
1043-0342 Journal Code: A12

Contract/Grant No.: HL42385, HL, NHLBI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

07805709 91324709

Efficient gene transfer and expression in primary B lymphocytes.

Overell RW; Weisser KE; Hess BW; Ziegler SF; Pleiman CM; Maliszewski C;
Grabstein KH

Department of Molecular Biology, Immunex Corporation, Seattle, WA 98101.

J Immunol Methods (NETHERLANDS) Jul 26 *1991*, 141 (1) p53-62, ISSN
0022-1759 Journal Code: IFE

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

06418000 88063000

Identification and gene mapping of a 14,700-molecular-weight protein
encoded by region E3 of group C *adenoviruses*.

Tollefson AE; Wold WS

Institute for Molecular Virology, St. Louis University School of
Medicine, Missouri 63110.

J Virol (UNITED STATES) Jan. *1988*, 62 (1) p33-9, ISSN 0022-538X
Journal Code: KCV

Contract/Grant No.: CA24710

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

06379229 88024229

Stable transfer of a mouse dihydrofolate reductase gene into a deficient
cell line using human *adenovirus* *vector*.

Ghosh-Choudhury G; Graham FL

Department of Biology, McMaster University, Hamilton, Ontario, Canada.

Biochem Biophys Res Commun (UNITED STATES) Sep 30 *1987*, 147 (3)
p964-73, ISSN 0006-291X Journal Code: 9Y8

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/5 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

06007231 86308231

Identification and mapping of Epstein-Barr virus early antigens and
demonstration of a viral gene activator that functions in trans.

Wong KM; Levine AJ

J Virol (UNITED STATES) Oct *1986*, 60 (1) p149-56, ISSN 0022-538X
Journal Code: KCV

Languages: ENGLISH

Document type: JOURNAL ARTICLE

5/3/6 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05983630 86284630
Vector expression of *adenovirus* type 5 Ela proteins: evidence for Ela autoregulation.
Smith DH; Kegler DM; Ziff EB
Mol Cell Biol (UNITED STATES) Oct *1985*, 5 (10) p2684-96, ISSN 0270-7306 Journal Code: NGY
Contract/Grant No.: GM 30760; P30CA-16087; 5 T32 GM07238-08 0051
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/7 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05788300 86089300
Development of a helper-independent human *adenovirus* *vector* and its use in the transfer of the herpes simplex virus thymidine kinase gene.
Haj-Ahmad Y; Graham FL
J Virol (UNITED STATES) Jan *1986*, 57 (1) p267-74, ISSN 0022-538X
Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/8 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05736435 86037435
Individual *adenovirus* type 5 *early* *region* 1A gene products elicit distinct alterations of cellular morphology and gene expression.
Roberts BE; Miller JS; Kimelman D; Cepko CL; Lemischka IR; Mulligan RC
J Virol (UNITED STATES) Nov *1985*, 56 (2) p404-13, ISSN 0022-538X
Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/9 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05398164 85014164
A plasmid *vehicle* suitable for the molecular cloning and characterization of mammalian promoters.
Featherstone MS; Naujokas MA; Pomerantz BJ; Hassell JA
Nucleic Acids Res (ENGLAND) Sep 25 *1984*, 12 (18) p7235-49, ISSN 0305-1048 Journal Code: O8L
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/10 (Item 10 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05241089 84165089

Infection of eucaryotic cells by helper-independent recombinant *adenoviruses*: *early* *region* 1 is not obligatory for integration of viral DNA.

Van Doren K; Hanahan D; Gluzman Y
J Virol (UNITED STATES) May *1984*, 50 (2) p606-14, ISSN 0022-538X
Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/11 (Item 11 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

05066978 83299978

A cell line that supports the growth of a defective *early* *region* 4 *deletion* mutant of human *adenovirus* type 2.

Weinberg DH; Ketner G
Proc Natl Acad Sci U S A (UNITED STATES) Sep *1983*, 80 (17) p5383-6,
ISSN 0027-8424 Journal Code: PV3
Contract/Grant No.: CA21309
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/12 (Item 12 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1996 Knight-Ridder Info. All rts. reserv.

04931345 83164345

Expression of *adenovirus* type 12 *early* *region* 1 in KB cells transformed by recombinants containing the gene.

Shiroki K; Saito I; Maruyama K; Fukui Y; Imatani Y; Oda KI; Shimojo H
J Virol (UNITED STATES) Mar *1983*, 45 (3) p1074-82, ISSN 0022-538X
Journal Code: KCV
Languages: ENGLISH
Document type: JOURNAL ARTICLE

5/3/13 (Item 1 from file: 55)
DIALOG(R)File 55:BIOSIS PREVIEWS(R)
(c) 1996 BIOSIS. All rts. reserv.

5246048 BIOSIS Number: 81013355

VECTOR EXPRESSION OF *ADENOVIRUS* TYPE 5 E-1A PROTEINS EVIDENCE FOR E-1A AUTOREGULATION

SMITH D H; KEGLER D M; ZIFF E B
KAPLAN CANCER CENT., N.Y. UNIV. MED. CENT., NEW YORK, N.Y. 10016.
MOL CELL BIOL 5 (10). 1985. 2684-2696. CODEN: MCEBD
Full Journal Title: Molecular and Cellular Biology
Language: ENGLISH

5/3/14 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abstracts Online
(c) 1996 UMI. All rts. reserv.

0972096 ORDER NO: AAD87-26803
MECHANISMS INVOLVED IN REGULATING THE *ADENOVIRUS* *EARLY* *REGION* 1B GENE
Author: DALIE, BARBARA L.
Degree: PH.D
Year: *1987*
Corporate Source/Institution: COL. OF MEDICINE AND DENTISTRY OF N.J.
GRAD. SCH. OF BIOMED. SCIENCE (0301)
Source: VOLUME 48/09-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 2557. / 74 PAGES

5/3/15 (Item 1 from file: 76)
DIALOG(R)File 76:Life Sciences Collection
(c) 1996 Cambridge Sci Abs. All rts. reserv.

01174919 1830856
Stable transfer of a mouse dihydrofolate reductase gene into a deficient
cell line using human *adenovirus* *vector*.
Ghosh Choudhury, G.; Graham, F.L.
Dep. Cell. and Struct. Biol., Univ. Texas Health Sci Cent., 7703 Floyd Curl
Dr., San Antonio, TX 78284, USA
BIOCHEM. BIOPHYS. RES. COMMUN. vol. 147, no. 3, pp. 964-973 (*1987.*)
DOCUMENT TYPE: Journal article LANGUAGE: ENGLISH
SUBFILE: Genetics Abstracts; Biochemistry Abstracts Part 2: Nucleic Acids

5/3/16 (Item 2 from file: 76)
DIALOG(R)File 76:Life Sciences Collection
(c) 1996 Cambridge Sci Abs. All rts. reserv.

01076914 1619371
Domain analysis of the *adenovirus* Ela protein.
Lyons, R.H.; Ferguson, B.Q.; Culp, J.S.; Rosenberg, M.
Smith, Kline and French Lab., Mol. Genet. Dep., 1500 Spring Garden St.,
Philadelphia, PA 19101, USA
RNA POLYMERASE AND THE REGULATION OF TRANSCRIPTION.
Reznikoff, W.S.; Gross, C.A.; Burgess, R.R.; Record, M.T., Jr.; Dahlberg,
J.E.; Wickens, M.P. (eds.)
ISBN: 0-444-01236-2
pp. 279-292 (*1987.*)
CONFERENCE: 16. Steenbock Symposium, Madison, WI (USA), 1986 Jul 13-17
DOCUMENT TYPE: Book; Conference paper LANGUAGE: ENGLISH
SUBFILE: Virology Abstracts; Genetics Abstracts; Biochemistry Abstracts
Part 2: Nucleic Acids

5/3/17 (Item 3 from file: 76)
DIALOG(R)File 76:Life Sciences Collection
(c) 1996 Cambridge Sci Abs. All rts. reserv.

01010047 1466373
Development of a helper-independent human *adenovirus* *vector* and its use
in the transfer of the herpes simplex virus thymidine kinase gene.

Haj Ahmad, Y.; Graham, F.L.

Dep. Biol., McMaster Univ., Hamilton, Ont. L8S 4K1, Canada

J. VIROL. vol. 57, no. 1, pp. 267-274 (*1986.*)

DOCUMENT TYPE: Journal article LANGUAGE: ENGLISH

SUBFILE: Biochemistry Abstracts Part 2: Nucleic Acids; Genetics Abstracts;
Virology Abstracts

?